Phase III trial of custirsen in combination with carboplatin and paclitaxel as first-line therapy in patients with advanced, unresectable non-small cell lung cancer.
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2012
At a glance
- Drugs Custirsen (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- 27 Sep 2012 Status changed from not yet recruiting to unconfirmed.
- 10 Mar 2011 Planned number of patients changed to 950.
- 23 Dec 2009 New trial record.